FDA advisory committee votes to keep Aprotinin on the market
After a 15-1 vote, an FDA advisory committee composed of experts in the field has recommended that sales of the blood loss prevention drug be permitted to continue. The drug, sold by Bayer AG under the name Trasylol, was initially approved by the FDA in 1993 to prevent the need for blood transfusions during bypass surgeries. The safety of the drug recently came into question when two studies released in 2006 linked the pharmaceutical to kidney problems, heart attacks, strokes, and even an increased risk of death. Although the committee recommended keeping the drug on the market, it did state that the concerns over the drug’s safety warranted further research.
Click here for the full article
Bookmark: 
